Amicogen, Inc.

Equities

A092040

KR7092040005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 19/05/2024 BST			5-day change	1st Jan Change
7,210 ^KRW	-2.44%		-0.41%	-4.63%

03-20	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 07:53 am

Amicogen, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 811.56 million compared to KRW 1,321.74 million a year ago. Net loss was KRW 8,710.05 million compared to KRW 1,844.93 million a year ago.

Basic loss per share from continuing operations was KRW 441 compared to KRW 96 a year ago. Diluted loss per share from continuing operations was KRW 441 compared to KRW 96 a year ago. Basic loss per share was KRW 441 compared to KRW 96 a year ago.

Latest news about Amicogen, Inc.

Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Beyond Cells announced that it has received KRW 3 billion in funding from Amicogen, Inc.	14/04/23	CI
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Lysando Ag and Amicogen Inc. Sign General Development Agreement	18/10/22	CI
Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding	17/07/22	CI
Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding	17/07/22	CI
Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Amicogen, Inc. announced that it has received KRW 8.7 billion in funding	10/05/22	CI
Amicogen, Inc. announced that it expects to receive KRW 8.7 billion in funding	08/05/22	CI
Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22/03/22	CI
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Amicogen, Inc. completed the acquisition of 30% stake in BIFIDO Co., Ltd from a group of shareholders.	13/09/21	CI
Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AG	01/09/21	CI
Amicogen, Inc. agreed to acquire a 30% stake in BIFIDO Co., Ltd from a group of shareholders for KRW 60.1 billion.	20/07/21	CI
Amicogen, Inc. agreed to acquire 8% stake in Lysando AG for KRW 28 billion.	14/07/21	CI
Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AG	13/07/21	CI
Amicogen, Inc. announced that it has received KRW 50 billion in funding	28/06/21	CI
Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding	22/06/21	CI
Beyond Cells announced that it expects to receive KRW 4.0188 billion in funding from Amicogen, Inc.	14/09/20	CI
Yoo's Pharm Corporation announced that it has received KRW 5 billion in funding from Amicogen, Inc.	14/01/20	CI
Yoo's Pharm Corporation announced that it expects to receive KRW 5 billion in funding from Amicogen, Inc.	13/01/20	CI

Chart Amicogen, Inc.

Duration

Period

More charts

Company Profile

Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AMICOGEN, INC.	-4.63%	291M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
BIONTECH SE	-12.38%	22.31B
ARGENX SE	-3.67%	21.6B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B
LEGEND BIOTECH CORPORATION	-24.50%	8.28B

Bio Therapeutic Drugs